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Abstract 14 
Docosahexaenoic acid (DHA) is an abundant nutrient from marine lipids: its specific 15 
biological effects have been investigated in human volunteers, taking into consideration the 16 
dose effects. We report herein that, at dosages below one g/day, DHA proved to be effective 17 
in lowering blood platelet function and exhibited an “antioxidant” effect. However, this was 18 
not anymore the case following 1.6g/day, showing then a U-shape response. The antioxidant 19 
effect has been observed in platelets as well as low-density lipoproteins, of which the redox 20 
status is assumed to be crucial in their relationship with atherosclerosis. Secondly, the 21 
oxygenated products of DHA, especially protectins produced by lipoxygenases, have been 22 
considered for their potential to affect blood platelets and leukocytes. It is concluded that 23 
DHA is an interesting nutrient to reduce athero-thrombogenesis, possibly through 24 
complementary mechanisms involving lipoxygenase products of DHA. 25 
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Introduction 30 
Docosahexaenoic acid (DHA, 22:6n-3) is an abundant long-chain polyunsaturated fatty acid 31 
(PUFA) of marine origin
(1)
. In addition to be a major PUFA of the brain and retina in 32 
animals
(2)
, DHA is well-known as a relevant nutrient which prevents adverse cardiovascular 33 
events
(3)
. Together with its precursor eicosapentaenoic acid (EPA, 20:5n-3), another major 34 
component of marine lipids
(4)
, DHA is one of the two main omega-3 long-chain PUFA 35 
believed to be responsible for protection against cardiovascular events
(5)
. However, it is worth 36 
mentioning the possible involvement in these biological events the third most abundant 37 
component in marine lipids 
(6)
, the intermediate between EPA and DHA, docosapentaenoic 38 
acid (DPA, 22:5n-3), and that of the omega-3 family precursor alpha-linolenic acid (ALA, 39 
18:3n-3)
(7)
. 40 
During the last decade, a series of oxygenated derivatives of DHA have been described with 41 
activities against inflammation, some speeding the resolution phase of inflammation, then 42 
playing an interesting role in the prevention of atherogenesis. The oxygenated metabolites 43 
have been named protectins and resolvins
(8,9)
. One protectin made by macrophages has been 44 
named maresin
(10)
. Lipoxygenases (LOX) are key enzymes in the generation of these 45 
derivatives, which makes the action of DHA quite specific and different from that of EPA that 46 
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is active through some of its cyclooxygenase (COX) products as well. In the eighties, DHA 47 
had already been reported as a fairly good substrate of blood platelet 12-LOX
(11)
. Also, its 48 
mono-hydroxylated metabolites produced through LOX have been found to be inhibitors of 49 
the thromboxane-induced platelet aggregation as well as blood vessel constriction
(12)
. 50 
This short review will consider the ex vivo effect of dietary DHA used at low dosage, and the 51 
in vitro biological effects of a double lipoxygenase product of DHA called protectin DX, in 52 
the frame of the cardiovascular risk. 53 
 54 
DHA supplementation in humans 55 
A large number of trials have been conducted with long-chain n-3 PUFA with various 56 
proportions of EPA and DHA, and also DPAn-3 when more or less crude fish oil or fish meat 57 
were used for supplementing the diet. It is generally assumed that those supplementations 58 
have preventive effects against cardiovascular events. However, depending on the status of 59 
volunteers (age, dietary habits, possible usage of drugs, etc) the benefits of such 60 
supplementations may be controversial. Indeed, a recent meta-analysis which did not take into 61 
account the different situations of the people participating in the trials concluded that “omega-62 
3 PUFA supplementation was not associated with a lower risk of all-cause mortality” (13). A 63 
post-review further indicates that “Subgroup analyses suggested that this could be because of 64 
a low absolute risk as a consequence of the state-of-the-art drug treatment”(14). 65 
Earlier, we have considered that the dosage in EPA-DHA supplementation could be an issue 66 
as their high level of unsaturation makes them highly susceptible to peroxidation that could be 67 
detrimental to their potential benefit. Relating to blood platelets that play a crucial role in the 68 
initiation of atherothrombogenesis, we first considered that the increased oxidative stress 69 
associated with aging
(15)
 could negatively affect the expected benefit of the intake of long-70 
chain n-3 PUFA. So, we conducted an assay with a small dosage of those (150mg DHA + 30 71 
mg EPA esterified in triglycerides), each day for six weeks. The main results at the platelet 72 
level were a significant accumulation of DHA in membrane ethanolamine phospholipids and 73 
an increase in platelet vitamin E, the latter being of interest because platelet vitamin E is 74 
lower in this population of elderly people compared to young adults, associated with a 75 
decrease in malondialdehyde (MDA) concentration
(16)
. Also, a trend in decreased platelet 76 
aggregation and basal thromboxane formation could be observed, but the most striking fact 77 
was a significant lowering of the diastolic blood pressure. In contrast, no differences could be 78 
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observed in a placebo group receiving the same amount of sunflower oil, which of course 79 
contained high proportion of linoleate and no n-3 PUFA
(16)
. 80 
More recently we have conducted another investigation with increasing intakes of pure DHA 81 
esterified in triglycerides (algal oil) in a population of middle-aged men (53-65 year-old) with 82 
each of them following the supplementation program (two weeks of successively 200, 400, 83 
800 and 1600 mg DHA per day), making each volunteer his own control. A significant dose-84 
dependent accumulation of DHA could be observed in platelet phospholipids, but platelet 85 
aggregation was only significantly lowered after the intermediate dosages (400 and 800 86 
mg/d). In terms of redox status, only the 200 mg/d dosage was able to increase platelet 87 
vitamin E. Most interesting was to find that urinary isoprostanes, a recognized marker of 88 
oxidative stress, were significantly decreased after 200mg/d and significantly increased after 89 
1600 mg/d
(17)
. It must be noticed that the other markers of the oxidative stress, taken into 90 
consideration in this study, were not significantly altered following the highest dosage. 91 
Regarding the plasma low-density lipoproteins (LDL), their phospholipids and cholesteryl 92 
esters dose-dependently accumulated DHA, but significant improvements of the redox status 93 
were observed after 200, 400 and 800 mg/d DHA intake only. This concerned vitamin E with 94 
the highest increase after 200 mg/d, and reciprocal U-shape curves for MDA, a global marker 95 
of oxidative stress, and the oxidizability of LDL to copper ions, with a decreased MDA and 96 
increased lag phase of oxidation in response to copper
(18)
. These results clearly indicate that 97 
low daily intake of DHA (lower than 1 g/d) allows expression of an “antioxidant” profile 98 
based on several blood markers. This beneficial profile was not any more observed following 99 
the highest dosage, with even a global increased oxidative stress as stated above with urinary 100 
isoprostanes. 101 
Overall, and although the two latter intervention studies in healthy humans have not been 102 
conducted on a long term basis, they clearly indicate that the amount of long-chain n-3 PUFA 103 
intake is an issue that must be taken into consideration. 104 
 105 
Oxygenated metabolism of DHA and biological effects 106 
Contrary to EPA, that has the structural feature of arachidonic acid (ARA) with an additional 107 
cis/Z double bond at carbon 17, DHA is not oxygenated into prostanoid-like products by 108 
cyclooxygenases (COX) although it may inhibit the enzymes by competition, especially 109 
against ARA
(19)
. DHA may however be hydroxylated into 13-hydroxylated derivative by 110 
COX-2 or into 17(R)-hydroxylated derivative if COX-2 is treated by aspirin, the latter 111 
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derivative being a substrate of the neutrophil 5-LOX to produce resolvins D1 and D2
(20)
. This 112 
production is likely to be very low as the rate conversion of DHA into its 17(R)-hydroxylated 113 
derivative has been found to be less than 1-5 % of the rate conversion of ARA into PGH2
(21)
. 114 
In contrast, DHA is a fairly good substrate of LOX to produce various hydroxylated end-115 
products after reduction of the hydroperoxide intermediates by glutathione peroxidase. They 116 
are 4- and 7-OH through 5-LOX, 11- and 14-OH through 12-/n-9-LOX and 17-OH through 117 
15-/n-6-LOX
(22)
. The oxygenation of DHA through the latter LOX has been studied in details 118 
for the production of protectin/neuroprotectin D1
(8)
. In this case the biosynthetic route seems 119 
to mimic leukotriene B4 production by 5-LOX from ARA, then leading to 10(R),17(S)diOH-120 
4Z,7Z,11E,13E,15Z,19Z-22:6
(23,24)
. 121 
A double 15-/n-6-LOX end-product can also be produced, which is a geometric and 122 
stereoisomer of PD1. It is 10(S),17(S)diOH-4Z,7Z,11E,13Z,15E,19Z-22:6 and has been 123 
named protectin DX (PDX)
(25)
. As mono-hydroxylated derivatives have been shown to inhibit 124 
the thromboxane-induced aggregation of human blood platelets
(12)
, we have investigated the 125 
inhibition of that function by PDX and some isomers. In summary, PDX inhibits dose-126 
dependently platelet aggregation induced by collagen, ARA and the stable thromboxane A2 127 
mimetic U-46619 (a stable analog of prostaglandin H2). The inhibition power of PDX towards 128 
the aggregation induced by collagen or ARA was the same, but the inhibition of the U-46619-129 
induced aggregation was around half, suggesting that PDX did not affect the release of ARA 130 
from phospholipids in response to collagen but equally inhibits platelet COX-1 and 131 
thromboxane A2 response
(26)
. The inhibition of COX-1 was confirmed by studying the 132 
oxygenation of radiolabelled ARA, which proved the specific inhibition of COX-1 as the 12-133 
/n-9-LOX activity was not affected. Interestingly, a stereoisomer of PDX (10(R) instead of 134 
10(S)), other double 15-/n-6-LOX end-products from ARA and 22:3n-6 were as inhibitory as 135 
PDX, providing they have the E,Z,E conjugated triene geometry. In contrast, isomers having 136 
an E,E,Z or E,E,E (all-trans) conjugated triene geometry were inactive. The E,Z,E conjugated 137 
trienes oxygenated PUFA have been collectively named “poxytrins”(26). It is worth noting that 138 
PD1, which has an E,E,Z conjugated triene motif, is described as an anti-inflammatory 139 
molecule but as a weak inhibitor of ADP-induced aggregation, without being further 140 
potentiated by aspirin treatment
(27)
. 141 
More recently, we have extended our investigations regarding PDX activities. First we found 142 
that it inhibits purified COX-1 and COX-2 with a slightly stronger inhibition of COX-2 143 
(submitted). Second, we addressed the possibility of inhibiting the reactive oxygen species 144 
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(ROS) generation in human neutrophils, as a previous work has shown that punicic acid, 145 
which exhibits a Z,E,Z conjugated triene motif, inhibits NADPH oxidase-induced ROS 146 
production
(28)
. Indeed, we found such an inhibition with a dose-dependent effect 
(29 & submitted)
. 147 
However, whereas PDX is active against platelet aggregation and COX activities in the sub-148 
micromolar range, the inhibition of ROS generation requires micromolar concentrations. 149 
Leukotriene production from ARA being an important feature in neutrophils, we also tested 150 
the effect of PDX upon the formation of 5-LOX products in these cells. No inhibition can be 151 
found while the endogenous COX-2 activity was inhibited at similar range concentrations as 152 
those inhibiting ROS production (submitted). This indicates that in addition to its potential for 153 
inhibiting platelet function, PDX may also exhibit some anti-inflammatory activity, likely 154 
through the inhibition of COX-2. 155 
 156 
Conclusion 157 
DHA is a nutrient with several beneficial effects in preventing athero-thrombogenesis if it is 158 
consumed in moderate amounts. In this respect, several international recommendations 159 
agreeing with half-a-gram per day seem reasonable to avoid some possible side-effects in 160 
terms of oxidative stress. Several mechanisms could contribute to the beneficial effects. 161 
Among them, the inhibition of COX activities and the DHA oxygenated products, mainly 162 
through LOX activities, may act by complementary effects such as inhibition of platelet 163 
aggregation and immune-competent cell function (Figure 1). Altogether the athero-164 
thrombogenesis could be reduced. However, it remains to prove that enough oxygenated 165 
products are generated in situ to account for the effects observed in vitro. 166 
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 176 
Figure: Summary of the DHA effect on blood platelets. 177 
DHA from the blood flow is partly taken up by platelets and mainly esterified into 178 
ethanolamine plasmalogens. This may be accompanied with an "antioxidant" effect as shown 179 
by in vitro enrichment
(30)
. DHA may be released by calcium-independent phospholipase A2 180 
(iPLA2)
(31)
, and be converted into 14-HDoHE by 12-/n-9-LOX to inhibit thromboxane action. 181 
Some non-esterified DHA entering platelets may directly be converted into 14-HDoHE. Non-182 
esterified DHA may also inhibit thromboxane A2 (TxA2) formation, in cPLA2-dependent 183 
activated platelets, through inhibition of COX-1. Besides platelets, DHA may be converted 184 
into PD1 and PDX by other cells doted of 15-/n-6-LOX such as endothelial cells and 185 
leukocytes, and PDX may inhibit platelet aggregation. 186 
PL-ARA & PL-DHA: ARA & DHA-containing phospholipids, respectively. TxS: 187 
thromboxane synthase. 188 
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